- Home
- UTHR vs MP Comparison
UTHR vs MP Comparison
Compare UTHR & MP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTHR
- MP
- Stock Information
- Founded
- UTHR 1996
- MP 2017
- Country
- UTHR United States
- MP United States
- Employees
- UTHR N/A
- MP N/A
- Industry
- UTHR Biotechnology: Pharmaceutical Preparations
- MP Metal Mining
- Sector
- UTHR Health Care
- MP Basic Materials
- Exchange
- UTHR Nasdaq
- MP Nasdaq
- Market Cap
- UTHR 13.8B
- MP 12.9B
- IPO Year
- UTHR 1999
- MP N/A
- Fundamental
- Price
- UTHR $405.02
- MP $63.59
- Analyst Decision
- UTHR Strong Buy
- MP Buy
- Analyst Count
- UTHR 15
- MP 8
- Target Price
- UTHR $449.13
- MP $61.00
- AVG Volume (30 Days)
- UTHR 902.7K
- MP 9.0M
- Earning Date
- UTHR 10-29-2025
- MP 11-06-2025
- Dividend Yield
- UTHR N/A
- MP N/A
- EPS Growth
- UTHR 17.94
- MP N/A
- EPS
- UTHR 25.63
- MP N/A
- Revenue
- UTHR $3,077,800,000.00
- MP $242,116,000.00
- Revenue This Year
- UTHR $13.89
- MP $41.97
- Revenue Next Year
- UTHR $5.68
- MP $145.91
- P/E Ratio
- UTHR $15.80
- MP N/A
- Revenue Growth
- UTHR 17.62
- MP 39.42
- 52 Week Low
- UTHR $266.98
- MP $13.40
- 52 Week High
- UTHR $436.95
- MP $82.50
- Technical
- Relative Strength Index (RSI)
- UTHR 71.35
- MP 45.68
- Support Level
- UTHR $395.00
- MP $61.60
- Resistance Level
- UTHR $401.62
- MP $65.62
- Average True Range (ATR)
- UTHR 13.35
- MP 3.38
- MACD
- UTHR 6.12
- MP -1.37
- Stochastic Oscillator
- UTHR 76.31
- MP 15.60
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
About MP MP Materials Corp.
MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America. The company is also developing a rare earth metal, alloy, and magnet manufacturing facility in Fort Worth, Texas. The company's operations are organized into two reportable segments: Materials and Magnetics.